Lupus Foundation of America1d
Cardiovascular Disease Event Prevalence Higher Among People with Systemic Lupus Erythematosus
In a new study, researchers investigated the prevalence of cardiovascular disease events (CVE) in people with systemic lupus ...
Lupus Foundation of America2d
Use of Hydroxychloroquine May Provide Protection Against Cardiovascular Events in People with Systemic Lupus Erythematosus
In a recent study, researchers explored the association between HCQ and the overall risk of CV events in people with SLE.
Lupus Foundation of America4d
Kezar Study Evaluates Potential New Treatment for People with Lupus Nephritis
The PALIZADE clinical study is evaluating zetomipzomib for the treatment of lupus nephritis, its side effects, and how it affects proteins in the urine. The PALIZADE clinical trial is made up of 3 ...
Lupus Foundation of America6d
Exploring Autoimmune Prevalence and X Chromosome Inactivation in Systemic Lupus Erythematosus
Autoimmune diseases, including systemic lupus erythematosus (SLE), are more common in women than men, and scientists are ...
Lupus Foundation of America8d
Hydroxychloroquine Monitoring Associated with Lower Hospital Visits in People with Lupus
A recent study found that regularly checking blood levels of hydroxychloroquine (HCQ, known commercially as Plaquenil®) may ...
Lupus Foundation of America9d
Central Retinal Artery Occlusion as a Potential Indicator for Systemic Lupus Erythematosus
An ophthalmologist conducted a visual examination which showed central retinal artery occlusion (CRAO), the blockage of a ...
Lupus Foundation of America9d
Advancing Research
Our approach is innovative and removes barriers to progress. Watch this short video about three of our bold research initiatives to better understand lupus in children and teens, improve early ...